Liana Gross-Martirosyan (Liana Martirosyan)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Decision Making

Transcription Factor

Top Venues

Clinical pharmacology and therapeutics

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Goedecke, Liana Gross-Martirosyan, Nathalie Gault, Karin Seifert, Daniel R Morales, Priya Bahri, Valerie Strassmann, Martin Huber, Sabine Straus
Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations. Pharmacoepidemiology and drug safety 33 (8) (2024)
Stefanie Prilla, Sophie Groeneveld, Alexandra C Pacurariu, María Clara Restrepo-Méndez, Patrice Verpillat, Carla Torre, Christian Gartner, Peter G M Mol, Frauke Naumann-Winter, Kieran C Breen, Nathalie Gault, Liana Gross-Martirosyan, Sylvie Benchetrit, Brian Aylward, Violeta Stoyanova-Beninska, Maura O'Donovan, Sabine Straus, Jesper Kjaer, Peter Arlett
Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases. Clinical pharmacology and therapeutics (2024)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)